Purpose: Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and in combination with fulvestrant in women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer previously treated with endocrine therapy.
Eli Lilly and Company announced that following a pre-planned interim analysis for MONARCH 3, the trial met its primary endpoint...
MONARCH 3 is a global Phase III, double-blind, placebo-controlled study, which evaluated the efficacy and safety of abemaciclib in combination...
Eli Lilly and Company announced that following a pre-planned interim analysis for MONARCH 2, an independent Data Monitoring Committee (DMC)...
Eli Lilly and Company announced that its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival (PFS)....
Eli Lilly and Company announced that interim results from the double-blind, placebo-controlled Phase III MONARCH 3 study evaluating Verzenio (abemaciclib),...
Eli Lilly announced that results from the Phase III MONARCH 2 study showed that LY 2835219 (abemaciclib) in combination with...
Eli Lilly and Company announced that Verzenio (abemaciclib) demonstrated a statistically significant improvement in overall survival in the Phase III...
Eli Lilly and Company announced results from the MONARCH 3 clinical trial, which will be presented in a late-breaking presentation during the 2023 San Antonio Breast Cancer Symposium (SABCS)
Eli Lilly and Company announced results from the MONARCH 1 Phase II study of abemaciclib, a cyclin-dependent kinase (CDK) 4...